A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
- Interventions
- Drug: JNJ-67856633
- Registration Number
- NCT03900598
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- Detailed Description
Non-Hodgkin lymphoma (NHL) represents a diverse set of diseases. Among them diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of NHL, accounting for 30 percent (%) to 40% of all newly diagnosed cases. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key mediator of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway and has been shown to play a critical role in different types of lymphoma, including activated B cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). JNJ-67856633 is a MALT1 inhibitor and will be administered orally. The study will evaluate the following: Dose Escalation (Part 1): One or more recommended Phase 2 dose (RP2Ds) of JNJ-67856633. Cohort Expansion (Part 2): JNJ-67856633 is well tolerated and achieves antitumor responses at the RP2D. The study consists of screening phase (less than or equal to 28 days before first dose), treatment phase (from Cycle 1 Day 1 till end of treatment visit \[within 30 (+7) days after the last dose\]) and post-treatment phase. A prescreening period may also apply to participants in select cohorts in Part 2. The total study duration will be approximately 4 years and 11 months. Efficacy assessments will include radiographic image assessments, positron emission tomography scan, bone marrow assessment, endoscopy or colonoscopy etc. Safety will be monitored throughout the study.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 226
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
- Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=)480 milliseconds based on the average of triplicate assessments performed no more than 5 minutes apart (plus minus [+-]3 minutes)
- Women of childbearing potential must have a negative highly sensitive serum (Beta human chorionic gonadotropin) at screening and prior to the first dose of study drug, and until 30 days after the last dose
- In addition to the user-independent, highly effective method of contraception, a male or female condom with or without spermicide is required, example, condom with spermicidal foam/gel/film/cream/suppository. Male condom and female condom should not be used together (due to risk of failure with friction)
- Men must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. Male participants should also be advised of the benefit for a female partner to use a highly effective method of contraception as condom may break or leak
- Known active central nervous system (CNS) involvement for dose escalation and specific expansion cohorts as determined by the study evaluation team (SET)
- Prior solid-organ transplantation
- Either of the following: a) Received an autologous stem cell transplant less than or equal to (<=)3 months before the first dose of study drug. b) Prior treatment with allogenic stem cell transplant <=6 months before the first dose of study drug, has evidence of graft versus host disease, or requires immunosuppressant therapy for graft versus host disease within the last 4 weeks
- History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study drug. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy which in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 1 year before the first dose of study drug. Concomitant malignancies that are unlikely to progress and/or preclude evaluation of study endpoints may be allowed after discussion with the Study Responsible Physician
- Prior treatment with a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part 2 (Cohort Expansion): JNJ-67856633 JNJ-67856633 Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1. Part 1 (Dose Escalation): JNJ-67856633 JNJ-67856633 Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
- Primary Outcome Measures
Name Time Method Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability Up to 4 years and 11 months An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Part 1: Dose-Limiting Toxicity (DLT) Approximately 21 days The DLTs are based on drug related adverse events and defined as any of the following events: any toxicity that would require discontinuation of treatment; and/or hematological / non-hematological toxicity of Grade 3 or higher.
- Secondary Outcome Measures
Name Time Method Part 1 and Part 2: Overall Response Rate (ORR) Up to 4 years and 11 months ORR is defined as the percentage of participants who have a partial response (PR) and complete response (CR) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), non-Hodgkin lymphoma and Waldenstrom macroglobulinemia response criteria.
JNJ-67856633 Plasma Concentrations Up to 4 years and 11 months Concentration assessment will be done to evaluate the effect of JNJ-67856633.
Part 1 and Part 2: Complete Response Rate Up to 4 years and 11 months Complete response rate is defined as the percentage of participants who achieve a best response of CR according to the iwCLL, non-Hodgkin lymphoma and Waldenstrom macroglobulinemia response criteria.
Part 1 and Part 2: Time to Response (TTR) Up to 4 years and 11 months TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR.
Part 1 and Part 2: Duration of Response (DoR) Up to 4 years and 11 months DoR is defined for participants who achieved PR or CR as the time between the date of initial documentation of PR or CR to the date of first documented evidence of disease progression or death, whichever comes first.
Trial Locations
- Locations (47)
City of Hope
🇺🇸Duarte, California, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Weill Cornell Medicine
🇺🇸New York, New York, United States
CHU de Nantes hotel Dieu
🇫🇷Nantes Cedex 1, France
Institut Curie
🇫🇷PARIS Cedex 5, France
Groupe Hospitalier Pitie Salpetriere
🇫🇷Paris, France
Centre hospitalier Lyon-Sud
🇫🇷Pierre Benite, France
Institut Universitaire du Cancer Toulouse - Oncopole
🇫🇷Toulouse, France
CHU Bretonneau
🇫🇷Tours Cedex 9, France
Institut Gustave Roussy
🇫🇷VILLEJUIF Cedex, France
Universitatsklinikum Munster
🇩🇪Münster, Germany
Universitatsklinikum Ulm
🇩🇪Ulm, Germany
Alexandra General Hospital of Athens
🇬🇷Athens, Greece
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna
🇮🇹Bologna, Italy
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
National Cancer Center Hospital
🇯🇵Chuo Ku, Japan
Tokai University Hospital
🇯🇵Isehara, Japan
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya-shi, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Hosp. Univ. Germans Trias I Pujol
🇪🇸Badalona, Spain
Hospital de Vall D'Hebron
🇪🇸Barcelona, Spain
Hosp Univ Fund Jimenez Diaz
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Quiron Madrid Pozuelo
🇪🇸Pozuelo de Alarcon, Spain
Hosp Clinico Univ de Salamanca
🇪🇸Salamanca, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
St Bartholomew's Hospital
🇬🇧London, United Kingdom
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
MD Anderson
🇺🇸Houston, Texas, United States
Monash Medical Centre
🇦🇺Clayton, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Australia
Linear Clinical Research Ltd
🇦🇺Nedlands, Australia
Scientia Clinical Research
🇦🇺Randwick, Australia
The First Affiliated Hospital of NanChang University
🇨🇳Nanchang, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
🇨🇳Tianjin, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳Xi'an, China
Hopital Claude Huriez
🇫🇷Lille, France